Table 1 Summary of patient characteristics
Total n = 962 | BRIM2 n = 132 | BRIM3 n = 337 | coBRIM n = 493 | |
|---|---|---|---|---|
Treatment | ||||
Vemurafenib monotherapy | 715 (74%) | 132 (100%) | 337 (100%) | 246 (50%) |
Vemurafenib + cobimetinib | 247 (26%) | 0 (0%) | 0 (0%) | 247 (50%) |
Sex | ||||
Male | 565 (59%) | 81 (61%) | 200 (59%) | 284 (58%) |
Female | 397 (41%) | 51 (39%) | 137 (41%) | 209 (42%) |
Age (years) | ||||
Median (IQR) | 55 (45–65) | 52 (40–63) | 56 (47–65) | 55 (45–66) |
Race | ||||
White | 923 (96%) | 130 (98%) | 333 (99%) | 460 (93%) |
Other | 14 (1%) | 2 (2%) | 4 (1%) | 8 (2%) |
Missing | 25 (3%) | 0 (0%) | 0 (0%) | 25 (5%) |
BRAF V600 mutation | ||||
V600E | 762 (79%) | 122 (92%) | 296 (88%) | 344 (70%) |
V600K | 98 (10%) | 10 (8%) | 33 (10%) | 55 (11%) |
Missing | 102 (11%) | 0 (0%) | 8 (2%) | 94 (19%) |
Stage | ||||
Unresectable IIIc | 54 (6%) | 0 (0%) | 20 (6%) | 34 (7%) |
M1a | 146 (15%) | 33 (25%) | 33 (10%) | 80 (16%) |
M1b | 162 (17%) | 18 (14%) | 62 (18%) | 82 (17%) |
M1c | 599 (62%) | 80 (61%) | 222 (66%) | 297 (60%) |
Missing | 1 (< 1%) | 1 (1%) | 0 (0%) | 0 (0%) |
ECOG PS | ||||
0 | 639 (66%) | 61 (46%) | 230 (68%) | 348 (71%) |
> 0 | 317 (33%) | 71 (54%) | 107 (32%) | 139 (28%) |
Missing | 6 (1%) | 0 (0%) | 0 (0%) | 6 (1%) |
Weight (kg) | ||||
Median (IQR) | 78 (66–91) | 76 (65–92) | 79 (66–89) | 78 (67–92) |
Missing | 7 (1%) | 0 (0%) | 4 (1%) | 3 (1%) |